I agree afford. I wasn't trying to imply that Baker Bros is more important than Woodford or that they are the all important end goal.
What I was trying to say, is that in my estimation, a phase 2 collaboration with big pharma would provide additional validation of the science that would be impossible for the likes of Baker Bros to ignore. If we have more firms like Woodford, Baker, etc., jump in, we will see a domino effect of other funds that follow suit. The combined buying from multiple large firms would have a dramatic impact on the share price (maybe even kick off a short squeeze if the shorts aren't hedged to the hilt with warrants). Hope that helps clarify.
Wonder if AF feels any different about the probability that L will eventually find approval with the market cap well above the threshold of the Feuerstein-Ratian rule. I would have loved for NWBO to be the one that busted his little theory. Oh well, approval will feel like appropriate revenge anyway.